Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603420 | 0.84 | CLK1 (0.41) | PIM1CDK5DYRK1AKDM4EPRKCI | |
| SCHEMBL30692017 | 0.76 | PARP1 (0.53) | AURKADAPK3JAK2ROCK2CHEK2 | |
| SCHEMBL243725 | 0.76 | PARP1 (0.53) | AURKADAPK3JAK2ROCK2CHEK2 | |
| SCHEMBL445595 | 0.75 | IMPDH2 (0.58) | AURKADAPK3JAK2ROCK2CHEK2 | |
| Bromide SCHEMBL2246198 | 0.74 | PARP1 (0.52) | AURKADAPK3JAK2ROCK2CHEK2 | |
| SCHEMBL10594346 | 0.73 | TNF (0.43) | CDK2KDM4ECDK4CCND1AHR | |
| Bromide SCHEMBL27922950 | 0.73 | IMPDH2 (0.56) | AURKADAPK3JAK2ROCK2CHEK2 | |
| SCHEMBL4955118 | 0.72 | IMPDH2 (0.43) | AURKADAPK3JAK2ROCK2CHEK2 | |
| SCHEMBL30780132 | 0.72 | KDM4A (0.50) | AURKADAPK3JAK2ROCK2CHEK2 | |
| SCHEMBL27153010 | 0.72 | KDM4A (0.50) | AURKADAPK3JAK2ROCK2CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506208-A | Pyrrolo isoquinolines as kinase inhibitors | NOVARTIS AG (CH) | 2009-08-12 | — | — | CN | claimed |
| CN-108026110-B | Fused tricyclic compounds as protein kinase inhibitors | 国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.CNIO) | 2022-02-08 | — | — | CN | disclosed |
| EP-3341376-B1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III F S P CNIO (ES) | 2020-12-23 | — | — | EP | disclosed |
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2019-02-19 | — | — | US | disclosed |
| US-20180244687-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2018-08-30 | — | — | US | disclosed |
| EP-3341376-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundacion del Sector Publico Estatal Centro Nacional de Investigaciones Oncologicas Carlos III (F.S.P. CNIO) (ES) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017033019-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (CNIO) (ES) | 2017-03-02 | — | — | WO | disclosed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| CN-101506208-A | Pyrrolo isoquinolines as kinase inhibitors | NOVARTIS AG (CH) | 2009-08-12 | — | — | CN | disclosed |
| EP-2064212-A1 | PYRROLO ISOQUINOLINES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008025512-A1 | PYRROLO ISOQUINOLINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
| EP-1109809-B1 | PYRROLOQUINOLINES FOR TREATMENT OF OBESITY | CEREBRUS PHARM LTD (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-6365598-B1 | FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | CDC7, CDK7, CDK17 | AURKA 38/4885DAPK3 650/4885JAK2 279/4885 |
| US-20100069360-A1 | ORGANIC COMPOUNDS | SLCO1B3, CYP3A7, SLCO1B1 | AURKA 1885/4885DAPK3 3490/4885JAK2 1238/4885 |
| US-20180244687-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK8, CDK18, CDK2 | AURKA 102/4885DAPK3 435/4885JAK2 952/4885 |
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | CDK8, CDK18, CDK2 | AURKA 102/4885DAPK3 435/4885JAK2 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.